ORPHA:137908
Hypotonia with lactic acidemia and hyperammonemia
Also known as: COXPD5 · Combined oxidative phosphorylation defect type 5
Query health: suspect — Only one of 3 strategies returned hits (phrase).
Publications
11
19.9th percentile
Trials
0
Interventional, condition-specific
Researchers
116
Distinct authors in sample
Gene link
MRPS22
Strong
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
This syndrome is characterized by severe , lactic acidemia and hyperammonaemia.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0012718
- MeSH:C567126
- OMIM:611719
- UMLS:C2673642
Additional Mondo synonyms (4)
MRPS22 combined oxidative phosphorylation deficiency · combined oxidative phosphorylation defect type 5 · combined oxidative phosphorylation deficiency caused by mutation in MRPS22 · combined oxidative phosphorylation deficiency type 5
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Strong — MRPS22
- LiteraturePresent
11 matched papers (5 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (MRPS22).
GenCC classification: Strong.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
11
11 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
11 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
5 in the last 10 years · high confidence · 19.9th percentile (publications denominator)
Phrase hits: 11 · MeSH hits: 0
Who's working on it?
116
Distinct author names in 11 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Kingsmore S2 papers · 2012Papers in Europe PMC
- 02Abali S1 paper · 2019
Department of Pediatric Endocrinology and Diabetes, Marmara University School of Medicine, Istanbul, Turkey.
Papers in Europe PMC - 03Abali ZY1 paper · 2019
Department of Pediatric Endocrinology, İstanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Papers in Europe PMC - 04Acuña-Alonzo V1 paper · 2015
1] Department of Genetics, Evolution and Environment, UCL Genetics Institute, University College London, London WC1E 6BT, UK [2] National Institute of Anthropology and History, Mexico City 4510, Mexico.
Papers in Europe PMC - 05Adhikari K1 paper · 2015
Department of Genetics, Evolution and Environment, UCL Genetics Institute, University College London, London WC1E 6BT, UK.
Papers in Europe PMC - 06Adkins RM1 paper · 2011
Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN 38103, USA. ronald.m.adkins@gmail.com
Papers in Europe PMC - 07Ahmad B1 paper · 2025
Department of Paediatrics, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Papers in Europe PMC - 08Al Bulayhi S1 paper · 2022
From the Division of Pediatric Neurology (Kentab, Al Bulayhi, Hamad, Al Wadei, Bashiri), Department of Pediatrics, King Khalid University Hospital, King Saud University Medical City, and from the Department of Pediatrics (Kentab, Bashiri), College of Medicine, King Saud University, and from the Department of Pediatric Neurology (Al Wadei), National Neuroscience Institute, King Fahad Medical City, Riyadh, Kingdom of Saudi Arabia.
Papers in Europe PMC - 09Al Wadei A1 paper · 2022
From the Division of Pediatric Neurology (Kentab, Al Bulayhi, Hamad, Al Wadei, Bashiri), Department of Pediatrics, King Khalid University Hospital, King Saud University Medical City, and from the Department of Pediatrics (Kentab, Bashiri), College of Medicine, King Saud University, and from the Department of Pediatric Neurology (Al Wadei), National Neuroscience Institute, King Fahad Medical City, Riyadh, Kingdom of Saudi Arabia.
Papers in Europe PMC - 10Al-Jasmi F1 paper · 2023
Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Hypotonia with lactic acidemia and hyperammonemia" OR "COXPD5" OR "Combined oxidative phosphorylation defect type 5" OR "MRPS22 combined oxidative phosphorylation deficiency" OR "combined oxidative phosphorylation deficiency caused by mutation in MRPS22" OR "combined oxidative phosphorylation deficiency type 5"
MeSH descriptor terms unioned into the query: Combined Oxidative Phosphorylation Deficiency 5
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Hypotonia with lactic acidemia and hyperammonemia" OR "COXPD5" OR "Combined oxidative phosphorylation defect type 5" OR "MRPS22 combined oxidative phosphorylation deficiency" OR "combined oxidative phosphorylation deficiency caused by mutation in MRPS22" OR "combined oxidative phosphorylation deficiency type 5" OR "Combined Oxidative Phosphorylation Deficiency 5" OR "MRPS22"
Recall-expansion terms: MRPS22
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, mesh, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T07:31:56.856Z